Health X Platform Limited (Sastasundar Ventures Ltd) (NSE: HEALTHX, BSE: 533259) is a Kolkata, West Bengal-based company in the Pharmaceutical Product Distribution industry. With a market capitalisation of ₹871 Cr, it ranks #1,660 by market cap among the 6,197 Indian listed companies on FinBizNet, and #3 of 13 in Pharmaceutical Product Distribution. At ₹273.00 (as of 19 Nov 2026), the share price is 24.8% below its 52-week high of ₹363.00 and 8.1% above its 52-week low of ₹252.50. The share price is down 5.9% over one year and down 13.1% over three months.
| Current Price | ₹273.00 |
|---|---|
| Market Cap | ₹871 Cr |
| NSE Symbol | HEALTHX |
| BSE Code | 533259 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Distributors > Pharmaceutical Product Distribution |
| P/E Ratio | 752.7 |
| Return on Equity | -0.18% |
| Return on Assets | -0.07% |
| 52-Week Range | ₹252.50 – ₹363.00 |
| 1-Year Price Change | -5.9% |
| 3-Month Price Change | -13.1% |
| Beta (1Y) | 0.28 |
| Dividend Yield | 0.00% |
| Headquarters | Kolkata, West Bengal |
| Website | www.sastasundarventures.com |
| Revenue | ₹484 Cr |
|---|---|
| Net Profit | ₹-13 Cr |
| Net Margin | -2.6% |
| EPS (Basic) | ₹-3.47 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Health X Platform Limited (Sastasundar Ventures Ltd) reported revenue of ₹484 Cr in Q2 FY27, up 60.7% from ₹301 Cr in Q2 FY26 and up 8.3% from ₹447 Cr in Q1 FY27. It posted a net loss of ₹13 Cr for the quarter, against a net loss of ₹15 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹286 Cr (Q4 FY25) to ₹484 Cr (Q2 FY27). The company reported a net loss in 3 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹484 Cr | −₹13 Cr | −2.6% |
| Q1 FY27 | ₹447 Cr | ₹2 Cr | 0.4% |
| Q4 FY26 | ₹374 Cr | −₹13 Cr | −3.5% |
| Q3 FY26 | ₹346 Cr | ₹0 Cr | 0.1% |
| Q2 FY26 | ₹301 Cr | −₹15 Cr | −5.1% |
| Q1 FY26 | ₹298 Cr | ₹27 Cr | 8.9% |
| Q4 FY25 | ₹286 Cr | ₹18 Cr | 6.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 74.07% of Health X Platform Limited (Sastasundar Ventures Ltd)'s shares as of Sept 2026, against 74.24% in Sept 2025 (−0.17 percentage points). Delivery averaged 73.0% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).
Health X Platform Limited operates a digital network of healthcare and portfolio management services in India. The company operates through the Financial Services and Healthcare Network segments. It is involved in the financing of loans; investment in shares and securities; and activities for pathology and marketing of healthcare and OTC products through e-commerce portal. The company also provides financial consultancy, professional fees, wealth management, financial planning, distribution, and related services, as well as diagnostic services, including pathological/radiological investigation. In addition, it operates digital platforms for healthcare, including the Sastasundar app, a consumer-focused digital healthcare platform consisting of pharmacy, diagnostics, and wellness; and retailershakti.com, a B2B digital platform for pharmaceutical and wellness products. The company was formerly known as Sastasundar Ventures Limited Limited and changed its name to Health X Platform Limited
1. Financial Services-This segment engages in financing loans and investment in shares and securities, as well as provides financial consultancy, professional, wealth management, financial planning, distribution, and related services. 2. Healthcare Network-This segment engages in food processing, and preservation and marketing of healthcare products through e-commerce portal www.sastasundar.com. 3. Other-NA 4. Unallocated-NA
1. Financial Services-1% 2. Healthcare Network-97.3% 3. Other-1.7%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Entero Healthcare Solutions Limited | ₹8,733 Cr | 74.6 | 8.28% | ₹2,087 Cr | +70.5% |
| Remus Pharmaceuticals Limited | ₹941 Cr | 26.1 | 13.78% | — | +2.5% |
| Health X Platform Limited (Sastasundar Ventures Ltd) | ₹871 Cr | 752.7 | -0.18% | ₹484 Cr | -5.9% |
| Aptus Pharma Limited | ₹837 Cr | 156.8 | — | — | +647.0% |
| Vasa Denticity Limited | ₹797 Cr | 76.5 | 6.68% | ₹87 Cr | -15.6% |
| Bijoy Hans Ltd | ₹523 Cr | — | — | — | +113.0% |
| Speciality Medicines Limited | ₹149 Cr | 11.5 | — | — | — |
| Vijaypd Ceutical Limited | ₹136 Cr | 23 | 9.53% | — | — |
| Royal Sense Limited | ₹39 Cr | 5.6 | — | — | -73.3% |
Listed by market capitalisation. Ratios are shown for context only.
Health X Platform Limited (Sastasundar Ventures Ltd) is trading at ₹273.00, with a market capitalisation of ₹871 Cr.
Health X Platform Limited (Sastasundar Ventures Ltd) operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Distributors > Pharmaceutical Product Distribution).
Health X Platform Limited (Sastasundar Ventures Ltd) has a P/E of 752.7 and a return on equity of -0.18%.
Health X Platform Limited (Sastasundar Ventures Ltd) is listed on the NSE under the symbol HEALTHX and on the BSE under the scrip code 533259.
Health X Platform Limited (Sastasundar Ventures Ltd)'s share price is down 5.9% over one year and down 13.1% over three months. Its 52-week range is ₹252.50 to ₹363.00.
In Q2 FY27, Health X Platform Limited (Sastasundar Ventures Ltd) reported revenue of ₹484 Cr and net profit of ₹-13 Cr, with basic EPS of ₹-3.47 (consolidated, parsed from the company's exchange filing).
Health X Platform Limited (Sastasundar Ventures Ltd) reported revenue of ₹484 Cr in Q2 FY27, up 60.7% from ₹301 Cr in Q2 FY26 and up 8.3% from ₹447 Cr in Q1 FY27.
Promoters held 74.07% of Health X Platform Limited (Sastasundar Ventures Ltd)'s shares as of Sept 2026, against 74.24% in Sept 2025 (−0.17 percentage points).
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.